

Brintellix Name Change Announcement

May 2, 2016

The U.S. Food and Drug Administration (FDA) has approved a brand name change for the antidepressant Brintellix (vortioxetine) to decrease the risk of prescribing and dispensing errors resulting from name confusion with the blood-thinning medicine Brilinta (ticagrelor). The new brand name of the drug will be Trintellix, and it is expected to be available starting in June 2016. No other changes will be made to the label or packaging, and the medicine is exactly the same.

Because of the lag time associated with manufacturing bottles with the new brand name, health care professionals and patients may continue to see bottles labeled with the brand name Brintellix during the transition period.

Health care professionals should check carefully to make sure they have prescribed or dispensed the correct medicine. During the transition to the new name change from Brintellix to Trintellix, prescribers can reduce the risk of name confusion by including the generic name of the medication they are ordering, in addition to the brand name and indication for use. Patients should make sure they have received the correct medicine. Trintellix tablets will look the same as the Brintellix tablets. Those having any questions or concerns should talk to their prescriber or pharmacist.

Healthcare professionals and patients are encouraged to report any adverse events or side effects related to the use of this product and/or quality problems to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

- ✓ Complete and submit the report online: www.fda.gov/MedWatch/report.htm
- ✓ Complete and return a form by mail (address on the pre-addressed form) or fax (1-800-FDA-0178).

[Call 1-800-332-1088 to request a reporting form or download a form at
<http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm>.]

Source: <http://www.fda.gov/Drugs/DrugSafety/ucm497942.htm>